Komori
Results presentation4506Sumitomo Pharma Co.,Ltd.Pharmaceuticals

Financial Results Briefing Materials for the Second Quarter of Fiscal 2026 (Fiscal Year Ending March 2027)

First-half revenue increased, driven by growth in U.S. products, while operating profit and net profit declined as the temporary earnings recorded in the previous year fell away. The full-year forecast was revised upward to reflect higher-than-expected sales of U.S. products and sales to Europe, and the company also plans to restore the year-end dividend to ¥15.

Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
250
¥100 million (increase in the full-year revenue forecast)
Wording
Conditional
How definitive the wording is.

Contents of this document

Results presentationSecond quarter of the fiscal year ending March 2026 (FY2026 and second quarter of the fiscal year ending March 2027)9 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,665 100 million+17.3%
Operating profit¥423 100 million -56.0%core basis
Ordinary income¥394 100 million -57.6%interim profit before tax
Net income¥382 100 million -61.3%interim profit attributable to owners of the parent
Selling, general and administrative expenses¥783 100 million core basis
Full-year earnings forecast
Revenue
¥5,650 100 million
Costs of sales
¥2,460 100 million
Gross profit
¥3,190 100 million
Selling, general and administrative expenses
¥1,640 100 million
Research and Development Expenses
¥520 100 million
Core operating profit
¥1,050 100 million
Operating profit
¥1,040 100 million
Pretax profit
¥990 100 million
Profit for the period attributable to owners of the parent
¥940 100 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Revenue106.2
Core operating profit140.4
Operating profit140.9
Profit for the period attributable to owners of the parent147.1
Total major products in the United States48.7
Total major products in Japan51
Orgovyx51.7
Gemtesa61
Myfembree60.5
リサイミック (product)57.8
Aptiom47.1
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing as planned, with a second-quarter plan achievement rate of 102% (Orgovyx) / a second-quarter plan achievement rate of 117% (Gemtesa), mainly due to temporary pricing effects
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Full-year sales revenue forecast
United States¥18.7 billion increase
OtherUp ¥5.4 billion year on year
Foreign Exchange Effects¥6.1 billion
Orgovyx full-year forecast variance
Quantity-$9 million
Price$14 million
Gemtesa full-year forecast variance
Quantity$12 million
Price$54 million
Gross profit by region
JapanUp ¥2.3 billion
United States¥19.1 billion increase
Other¥2.6 billion increase
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rateFY2026 revised forecast: $1 = ¥157.00
New initiatives
  • Began direct sales of Zeprion and Zeprion TRI in Japan
  • Conducted the first transplant in October 2026 in the post-marketing clinical trial (Phase 4) for Amschepri
  • Plans to begin a human challenge study of a universal influenza vaccine by the end of FY2026
  • Plans to restore the year-end dividend to ¥15
Key KPIsA metric the company considers important as a management benchmark.
  • Orgovyx U.S. sales volumeDisplayed in graph
  • Total Gemtesa prescriptionsDisplayed in graph
    Year on year against the same period last yearContinued increase
  • New Gemtesa prescriptionsDisplayed in graph
    Year on year against the same period last yearContinued increase
  • Number of clinical trial patients12 Example
Unit price and quantity metricsThese figures show sales broken down by price and volume.
  • Volume and priceVolume -9, price 14 (variance from the previous forecast)
    ProductOrgovyx
  • Volume and priceVolume 12, price 54 (variance from the previous forecast)
    ProductGemtesa
Segment results
Japan
Revenue
¥446 100 million+4.2%
Gross profit
¥196 100 million-6.2%
United States
Revenue
¥1,978 100 million+26.0%
Gross profit
¥1,197 100 million+19.5%
Other
Revenue
¥241 100 million-11.7%
Gross profit
¥36 100 million-77.9%
Financial targets
ROE
Previous forecast20.3 %
Revised forecast24.1 %
ROIC
Previous forecast15.1 %
Revised forecast17.6 %
Annual Dividend
Annual¥15 (year-end dividend forecast)
End of period¥15
Contents of this document
ItemDetails
Document typeResults presentation
Fiscal Period CoveredSecond quarter of the fiscal year ending March 2026 (FY2026 and second quarter of the fiscal year ending March 2027)
Net Sales¥2,665 100 million (YoY +17.3%)
Operating profit¥423 100 million (core basis) (YoY -56.0%)
Ordinary income¥394 100 million (interim profit before tax) (YoY -57.6%)
Net income¥382 100 million (interim profit attributable to owners of the parent) (YoY -61.3%)
Selling, general and administrative expenses¥783 100 million (core basis)
Full-year earnings forecastRevenue ¥5,650 100 million / Costs of sales ¥2,460 100 million / Gross profit ¥3,190 100 million / Selling, general and administrative expenses ¥1,640 100 million / Research and Development Expenses ¥520 100 million / Core operating profit ¥1,050 100 million / Operating profit ¥1,040 100 million / Pretax profit ¥990 100 million / Profit for the period attributable to owners of the parent ¥940 100 million
Progress against full-year forecastRevenue 106.2 / Core operating profit 140.4 / Operating profit 140.9 / Profit for the period attributable to owners of the parent 147.1 / Total major products in the United States 48.7 / Total major products in Japan 51 / Orgovyx 51.7 / Gemtesa 61 / Myfembree 60.5 / リサイミック (product) 57.8 / Aptiom 47.1
Self-assessment against the planProgressing as planned, with a second-quarter plan achievement rate of 102% (Orgovyx) / a second-quarter plan achievement rate of 117% (Gemtesa), mainly due to temporary pricing effects
Segment resultsJapan Revenue ¥446 100 million (YoY +4.2%) / Gross profit ¥196 100 million (YoY -6.2%) / United States Revenue ¥1,978 100 million (YoY +26.0%) / Gross profit ¥1,197 100 million (YoY +19.5%) / Other Revenue ¥241 100 million (YoY -11.7%) / Gross profit ¥36 100 million (YoY -77.9%)
Breakdown of Factors Affecting the ChangeFull-year sales revenue forecast United States ¥18.7 billion increase / Other Up ¥5.4 billion year on year / Foreign Exchange Effects ¥6.1 billion / Orgovyx full-year forecast variance Quantity -$9 million / Price $14 million / Gemtesa full-year forecast variance Quantity $12 million / Price $54 million / Gross profit by region Japan Up ¥2.3 billion / United States ¥19.1 billion increase / Other ¥2.6 billion increase
Key KPIsIndicator name Orgovyx U.S. sales volume / Value Displayed in graph / Year on year against the same period last year Not disclosed, Indicator name Total Gemtesa prescriptions / Value Displayed in graph / Year on year against the same period last year Continued increase, Indicator name New Gemtesa prescriptions / Value Displayed in graph / Year on year against the same period last year Continued increase, Indicator name Number of clinical trial patients / Value 12 Example / Year on year against the same period last year Not disclosed
Unit price and quantity metricsProduct Orgovyx / Indicator Volume and price / Value Volume -9, price 14 (variance from the previous forecast), Product Gemtesa / Indicator Volume and price / Value Volume 12, price 54 (variance from the previous forecast)
Assumptions Underlying the Business OutlookExchange rate FY2026 revised forecast: $1 = ¥157.00
Financial targetsROE Previous forecast 20.3 % / Revised forecast 24.1 % / ROIC Previous forecast 15.1 % / Revised forecast 17.6 %
Annual DividendAnnual ¥15 (year-end dividend forecast) / Interim Not disclosed / End of period ¥15
New initiativesBegan direct sales of Zeprion and Zeprion TRI in Japan, Conducted the first transplant in October 2026 in the post-marketing clinical trial (Phase 4) for Amschepri, Plans to begin a human challenge study of a universal influenza vaccine by the end of FY2026, Plans to restore the year-end dividend to ¥15
Items this document does not state (13)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In the first half, growth in the United States exceeded the decline in the Asia business. The upward revision to the full-year forecast reflects higher-than-expected U.S. sales of Gemtesa and other products, higher-than-expected sales to Europe, and the limited increase in the cost of sales that had been assumed. Meanwhile, first-half operating profit and net profit declined because other income recorded in the previous year fell away and research and development expenses, selling expenses, and general and administrative expenses increased.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Briefing Materials for the Second Quarter of Fiscal 2026 (Fiscal Year Ending March 2027) | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure | Komori